Investor Bain Capital Life Sciences Fund, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Bain Capital Life Sciences Fund, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-09-15 13G XFOR / X4 Pharmaceuticals, Inc. 2,436,526 2,436,588
2025-08-13 13D XFOR / X4 Pharmaceuticals, Inc. 16,915,784 2,436,526
2025-02-14 13G/A ANNX / Annexon, Inc. 5,974,716 5,249,069
2024-11-14 13G/A ANNX / Annexon, Inc. 8,061,719 5,974,716
2024-02-13 13G/A ANNX / Annexon, Inc. 2,940,627 8,061,719
2024-02-13 13G/A XFOR / X4 Pharmaceuticals, Inc. 12,202,510 16,915,784
2024-01-22 13G/A PHVS / Pharvaris N.V. 2,885,266 1,967,093
2023-06-23 13G/A PHVS / Pharvaris N.V. 2,885,266 2,885,266
2023-05-30 13G/A ANNX / Annexon, Inc. 4,886,616 2,940,627
2023-02-14 13G/A ANNX / Annexon, Inc. 2,940,627 4,886,616
2023-02-14 13G/A XFOR / X4 Pharmaceuticals, Inc. 2,886,542 12,202,510
2022-08-17 13D/A DVAX / Dynavax Technologies Corporation 7,634,045 4,912,610
2022-08-08 13D/A ARQT / Arcutis Biotherapeutics, Inc. 2,721,436 2,721,436
2022-05-27 13D/A ARQT / Arcutis Biotherapeutics, Inc. 3,609,796 2,721,436
2022-02-14 13G/A XFOR / X4 Pharmaceuticals, Inc. 1,648,485 2,886,542
2022-02-14 13G RPID / Rapid Micro Biosystems, Inc. 7,651,369
2021-08-27 13D/A DVAX / Dynavax Technologies Corporation 10,415,000 7,634,045
2021-08-11 13D/A DVAX / Dynavax Technologies Corporation 11,771,708 10,415,000
2021-06-11 13D/A DVAX / Dynavax Technologies Corporation 10,895,773 11,771,708
2021-03-26 13D/A APTX / Aptinyx Inc. 8,066,113 8,066,113
2021-02-19 13G PHVS / Pharvaris N.V. 2,885,266
2021-02-16 13G/A MRNS / Marinus Pharmaceuticals, Inc. 5,390,922 1,298,178
2021-02-16 13G ANNX / Annexon, Inc. 2,940,627
2021-02-16 13G/A US2103731061 / Constellation Pharmaceuticals Inc 2,561,350 1,270,003
2021-02-16 13G/A REPL / Replimune Group, Inc. 2,575,360 0
2021-02-08 13D/A ARQT / Arcutis Biotherapeutics, Inc. 3,609,796 3,609,796
2020-12-14 13D/A DRNA / Dicerna Pharmaceuticals Inc 3,690,803 2,786,247
2020-10-27 13D/A APTX / Aptinyx Inc. 5,042,297 8,066,113
2020-05-28 13D/A DVAX / Dynavax Technologies Corporation 8,730,707 10,895,773
2020-03-12 13D/A DVAX / Dynavax Technologies Corporation 8,452,235 8,730,707
2020-02-14 13G/A MRNS / Marinus Pharmaceuticals, Inc. 4,574,492 5,390,922
2020-02-07 13D ARQT / Arcutis Biotherapeutics, Inc. 3,609,796
2020-01-16 13D/A APTX / Aptinyx Inc. 2,018,481 5,042,297
2019-12-09 13G XFOR / X4 Pharmaceuticals, Inc. 1,648,485
2019-12-06 13D/A DRNA / Dicerna Pharmaceuticals Inc 5,047,637 3,690,803
2019-11-21 13D/A DRNA / Dicerna Pharmaceuticals Inc 6,630,610 5,047,637
2019-10-11 13G US2103731061 / Constellation Pharmaceuticals Inc 2,561,350
2019-08-22 13D DVAX / Dynavax Technologies Corporation 8,452,235
2019-05-31 13D/A DRNA / Dicerna Pharmaceuticals Inc 8,077,899 6,630,610
2019-02-14 13G/A MRNS / Marinus Pharmaceuticals, Inc. 3,608,127 4,574,492
2018-08-01 13G REPL / Replimune Group, Inc. 2,575,360
2018-07-03 13D APTX / Aptinyx Inc. 2,018,481
2017-12-19 13G/A MRNS / Marinus Pharmaceuticals, Inc. 4,762,511 3,608,127
2017-12-19 13D/A DRNA / Dicerna Pharmaceuticals Inc 7,459,625 8,077,899
2017-09-28 13G MRNS / Marinus Pharmaceuticals, Inc. 4,762,511
2017-09-18 13D/A DRNA / Dicerna Pharmaceuticals Inc 7,088,996 7,459,625
2017-04-13 13D DRNA / Dicerna Pharmaceuticals Inc 7,088,996